{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:08Z","timestamp":1788648848576,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.semarthrit.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T02:40:50Z","timestamp":1550198450000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-5634","authenticated-orcid":false,"given":"Helena","family":"Florez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Monegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2019.02.007_bib0001","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0002","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0003","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0004","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0006","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","author":"Lamy","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000979","article-title":"Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases","author":"Anagnostis","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0009","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0010","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0013","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-018-0436-y","article-title":"Certainties and uncertainties about denosumab discontinuation","volume":"103","author":"Tsourdi","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0017","first-page":"12","article-title":"Effects and management of denosumab discontinuation","author":"Chapurlat","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0019","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00198-017-4334-3","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis","volume":"29","author":"Niimi","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0022","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cen.13867","article-title":"Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman","volume":"90","author":"De Sousa","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0023","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jbspin.2008.07.017","article-title":"Radiographic methods for evaluating osteoporotic vertebral fractures","volume":"76","author":"Grados","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.02.007_bib0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0026","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0027","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1359\/jbmr.070505","article-title":"Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women","volume":"22","author":"Ivaska","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0028","article-title":"Multiple vertebral fractures after denosumab discontinuation","volume":"180","author":"Tjelum","year":"2018","journal-title":"Ugeskr L\u00e6ger"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0029","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0031","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0032","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0033","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","article-title":"Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial","volume":"20","author":"Tsai","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0034","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone Loss After Denosumab: only Partial Protection with Zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0035","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0036","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2019.02.007_bib0037","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rce.2015.08.003","article-title":"Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)","volume":"215","author":"Gonz\u00e1lez-Mac\u00edas","year":"2015","journal-title":"Rev Clin Esp"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218307005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218307005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:58:11Z","timestamp":1758733091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218307005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0049017218307005"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}